

201119013B

厚生労働科学研究費補助金
がん臨床研究事業

再発小細胞肺癌に対する
標準的治療法の確立に関する研究

平成21年度～23年度 総合研究報告書

研究代表者 後藤 功一

平成 24 (2012) 年 4 月

厚生労働科学研究費補助金
がん臨床研究事業

**再発小細胞肺癌に対する
標準的治療法の確立に関する研究**

平成21年度～23年度 総合研究報告書

研究代表者 後藤 功一

平成 24 (2012) 年 4 月

目 次

I. 総合研究報告	
再発小細胞肺癌に対する標準的治療法の確立に関する研究-----	1
後藤功一	
II. 研究成果の刊行に関する一覧表	----- 15
III. 研究成果の刊行物・別刷	----- 28

I. 総合研究報告

厚生労働科学研究費補助金（がん臨床研究事業）

（総合）研究報告書

再発小細胞肺癌に対する標準的治療法の確立に関する研究

研究代表者 後藤 功一

独立行政法人国立がん研究センター東病院

呼吸器腫瘍科呼吸器内科外来医長

研究要旨

再発小細胞肺癌に対する標準治療の確立を目的に、標準治療と見なされているノギテカン(NGT)療法に対して、我が国で新しく開発されたシスプラチン+エトポシド+イリノテカン(PEI)療法の優越性を多施設共同第III 相比較試験において検証する。本研究は、平成 18 年 8 月に Japan Clinical Oncology Group (JCOG)プロトコール審査委員会の承認を経て、平成 18 年 9 月 20 日より開始となった。国立がん研究センター運営費交付金研究開発費 20 指-02 班の参加施設を中心に組織された 40 施設において、施設倫理委員会(IRB)の承認を得たうえで症例が登録され、平成 24 年 3 月 13 日現在 151 例が登録されている。症例集積ペースが予定よりも遅いため、登録期間を 2 年間延長し、今後約 2 年間で症例集積が完了する予定である。

研究分担者

田村友秀	国立がん研究センター中央病院	科長	木浦勝行	岡山大学大学院	
森 清志	栃木県立がんセンター	部長		医歯薬学総合研究科	教授
岡本浩明	横浜市立市民病院	部長	河原正明	国立病院機構近畿中央胸部疾患	
山本信之	静岡県立静岡がんセンター	副院長		センター (平成 21 年度)	
横山 晶	新潟県立がんセンター新潟病院	院長	安宅信二	近畿中央胸部疾患センター	部長
樋田豊明	愛知県がんセンター中央病院	部長	根来俊一	兵庫県立がんセンター (平成 21 年度)	
今村文生	大阪府立成人病センター	部長	里内美弥子	兵庫県立がんセンター	部長
松井 薫	大阪府立呼吸器・アレルギー		西條長宏	近畿大学医学部	特任教授
	医療センター (平成 21 年度)		瀬戸貴司	九州がんセンター	医師
平島智徳	大阪府立呼吸器・アレルギー		工藤新三	大阪市立大学大学院医学研究科	准教授
	医療センター	部長	湊 浩一	群馬県立がんセンター	医療局長
中川和彦	近畿大学医学部	教授	澤 祥幸	岐阜市民病院	部長
武田晃司	大阪市立総合医療センター	部長	西尾誠人	がん研究会有明病院	副部長
			野上尚之	四国がんセンター	医長

A. 研究目的

再発小細胞肺癌（初回治療が奏効して、治療終了から 90 日以上経過して再発を認めた sensitive relapse）を対象にして、現在の標準的治療法と見なされるノギテカン(NGT)療法に対するシスプラチン+エトポシド+イリノテカン療法(PEI 療法)の優越性を検証することを目的とする。

B. 研究方法

全国 40 施設の研究グループによる多施設共同第 III 相比較試験で、エンドポイントは生存期間である。生存期間中央値 (MST) を 8 ヶ月から 12 ヶ月に向上させることを見込んでいる。

対象患者は、再発小細胞肺癌（初回治療が奏効して、治療終了から 90 日以上経過して再発を認めた sensitive relapse）であり、小細胞肺癌に対する外科的切除術の既往がなく、初回治療としてプラチナ製剤を含む併用化学療法または放射線化学療法を受けており、75 才以下、ECOG Performance Status (PS) 0-2、主要臓器機能が保持されており、患者本人の自由意思による文書同意が得られた患者である。

JCOG データーセンターでの中央登録、無作為化割り付けを行う。なお、割付調整因子は、PS、再発時病期、施設である。

治療内容は、NGT 療法、あるいは PEI 療法を行う。NGT 療法は、ノギテカン 1.0 mg/m^2 (day 1-5)、3 週間隔、4 コースとする。PEI 療法は、第 1 週目：シスプラチン (25 mg/m^2 , day 1) + エトポシド (60 mg/m^2 , day 1-3)、第 2 週目：シスプラチン (25 mg/m^2 , day 1) + イリノテカン (90 mg/m^2 , day 1) の 2 週間を 1 コースとして 5 コース (計 10 週) の治療法である。PEI 療法は、1 コース目の第 8 日目より G-CSF を抗癌剤投与日以外は連日投与する。

最終解析は症例集積終了 1 年後、中間解析は 1 回、安全性モニタリングは原則年 2 回。予定症例数は 180 例で、集積期間は当初は 4 年の予定であったが、症例集積ペースが遅いため、2 年延長し、6 年を予定している。

(倫理面への配慮)

参加患者の安全性確保については、適格条件やプロトコル治療の中止変更規準を厳しく設けており、試験参加による不利益は最小化される。また、「臨床研究に関する倫理指針」およびヘルシンキ宣言などの国際的倫理原則に従い以下を遵守する。

1) 研究実施計画書の IRB 承認が得られた施設のみから患者登録を行う。

2) すべての患者に登録前に十分な説明と理解に基づく自発的同意を本人より文書で得る。

3) データの取り扱い上、直接個人が識別できる情報を用いず、かつデータベースのセキュリティを確保し、個人情報保護を厳守する。

4) JCOG のプロトコル審査委員会、効果・安全性評価委員会、監査委員会、放射線治療委員会などによる第三者的監視を受けることを通じて、科学性と倫理性の確保に努める。

C. 研究結果

国立がん研究センター運営費交付金研究開発費 20 指-02「呼吸器悪性腫瘍に対する標準治療確立のための多施設共同研究」班の参加施設を中心に全国の肺癌臨床研究の主要 40 施設で研究グループを組織した。

JCOG プロトコル作成支援機構および審査機構の協力を受け、JCOG 運営委員会において研究コンセプトが承認され、平成 19 年 8 月に JCOG プロトコル審査委員会の承認を経て、平成 19 年 9 月 20 日より本試験を開始した。施設 IRB の承認を得て、平成 20 年 1 月より本格的に症例登録が始まり、平成 24 年 3 月 13 日現在 151 例が登録されている。症例集積ペースが予定よりも遅いため、登録期間を 2 年間延長し、今後約 2 年間で症例集積が完了する予定である。なお、平成 22 年 9 月 11 日 JCOG 効果・安全性評価委員会の中間解析審査において本試験の継続が承認されている。

D. 考察

小細胞肺癌は全肺癌の 10-15% を占め、非小細胞肺癌に比べると化学療法や放射線療法の感受性が高く、初回治療に対する奏効率は限局型で 80-100%、進展型で 60-80% である。しかし、80-90% の小細胞肺癌は再発を来し、5 年生存率は限局型で約 25%、進展型で 0-5% であり、小細胞がん全体の 5 年生存率は 10% 未満と不良である。再発後の化学療法に対する反応は悪く、再発から死亡までの MST は 3-4 ヶ月と言われて来た。

近年、再発小細胞肺癌は、初回化学療法が奏効し、治療終了から 60-90 日以上経過して再発を認める sensitive relapse と、初回治療に奏効しない、あるいは奏効しても 60-90 日以内に再発を認める refractory relapse の 2 つに分類されて、臨床研究が行われてきた。これは、この 2 群で化学療法の効果や生存期間に差を認めるためである。例えば、NGT 療法でみると、奏効率、MST は、sensitive relapse では 14-37%、

25-37 週、refractory relapse では 6-11%、16-20 週である。

現在までに再発小細胞肺癌 (sensitive relapse) を対象とした 4 つの大規模な第 III 相試験が報告されている。NGT 療法とシクロホスファミド+アドリアマイシン+ビンクリスチン (CAV) 療法を比較した第 III 相試験では、MST:25.0 週対 24.7 週と有意差を認めなかったが、再発に伴う症状の改善では NGT 療法が優れていた。NGT 療法の経口投与方法と静脈投与方法の比較試験では、奏効率、生存に有意差を認めず、毒性も同程度であった。また、NGT 療法の経口投与と無治療の第 III 相試験では、NGT 療法の有意な MST の延長 (26 週対 14 週) を認めた。2011 年の米国臨床腫瘍学会 (ASCO) では、NGT 療法とアムルビシン療法の第 III 相試験の結果が報告されたが、生存に有意差を認めなかった。再発小細胞肺癌に対する標準的化学療法は確立していないが、上記 4 つの第 III 相試験の結果に基づいて、世界的に NGT 療法が再発小細胞肺癌に対する標準治療とみなされている。そこで、再発小細胞肺癌 (sensitive relapse) に対する標準治療の確立を目指して、NGT 療法と我々が開発した PEI 療法の第 III 相比較試験を開始した。

E. 結論

再発小細胞肺癌の予後改善を目的とした「再発小細胞肺癌に対する標準的治療法の確立に関する研究」では、「再発小細胞肺癌に対する NGT 療法と PEI 療法を比較する第 III 相試験 (JCOG0605)」を平成 18 年 9 月 20 日より多施設共同試験として開始し、平成 24 年 3 月 13 日現在 151 例が登録され、症例集積を継続中である。

F. 研究発表

1. 論文発表

<平成 23 年度>

1. Naito, T., Tanaka, F., Ono, F., Yoneda, K., Takahashi, T., Murakami, H., Nakamura, Y., Tsuya, A., Kenmotsu, H., Shukuya, T., Kaira, K., Koh, Y., Endo, M., Hasegawa, S., Yamamoto, N. Prognostic impact of circulating tumor cells in patients with small-cell lung cancer. *J Thorac Oncol*, 7(3):512-519, 2012.
2. Okamoto, I., Yoshioka, H., Takeda, K., Satouchi, M., Yamamoto, N., Seto, T., Kasahara, K., Miyazaki, M., Kitamura, R., Ohyama, A., Hokoda, N., Nakayama, H., Yoshihara, E., Nakagawa, K. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced

non-small cell lung cancer. *J Thorac Oncol*. 7(2):427-33, 2012.

3. Sekine, I., Sumi, M., Ito, Y., Horinouchi, H., Nokihara, H., Yamamoto, N., Kunitoh, H., Ohe, Y., Kubota, K., Tamura, T. Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy with Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*, 82(2):953-9, 2012.
4. Saito, H., Nakagawa, K., Takeda, K., Iwamoto, Y., Ando, M., Maeda, M., Katakami, N., Nakano, T., Kurata, T., Fukuoka, M. Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Non-small Cell Lung Cancer and a Performance Status of 2: West Japan Thoracic Oncology Group 0004. *Am J Clin Oncol*, 35(1):58-63, 2012.
5. Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E., McCormack, R., Saijo, N., Mok, T., Fukuoka, M. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer. *J Thorac Oncol*. 7(1):115-21, 2012.
6. Saijo N. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. *Cancer Treat Rev*. 38(1):63-7, 2012.
7. Tamiya M, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Yasue T, Matsuura Y, Hirashima T, Kawase I. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bonemetastasis from lung cancer. *Med Oncol*. 29(1):215-18, 2012.
8. Shimada, Y., Niho, S., Ishii, G., Hishida, T., Yoshida, J., Nishimura, M., Yoh, K., Goto, K., Ohmatsu, H., Ohe, Y., Nagai, K. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. *Lung Cancer*. 75(3):368-73, 2012.
9. Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J., Higashiyama, M., Kodama, K., Imamura, F., Kato, K. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. *Clin Cancer Res*. 17(24):7808-15, 2011.
10. Shukuya, T., Takahashi, T., Naito, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Murakami, H., Harada, H., Mitsuya, K., Endo, M., Nakasu, Y., Takahashi, K., Yamamoto, N.

- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. *Lung Cancer*. 74(3):457-61, 2011.
11. Tagawa, T., Kometani, T., Yamazaki, K., Okamoto, T., Wataya, H., Seto, T., Fukuyama, S., Osoegawa, A., Hirai, F., Sugio, K., Ichinose, Y. Prognosis and therapeutic response according to the World Health Organization histological classification in advanced thymoma. *Surg Today*. 41:1599-1604, 2011.
 12. Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., Nokihara, H., Ohe, Y., Yokota, J., Uramoto, H., Yasumoto, K., Kiura, K., Higashiyama, M., Oda, M., Saito, H., Yoshida, J., Kondoh, K., Noguchi, M. Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. *J Thorac Oncol*. 6(12):2011-2017, 2011.
 13. Ichinose, Y., Seto, T., Sasaki, T., Yamanaka, T., Okamoto, I., Takeda, K., Tanaka, M., Katakami, N., Sawa, T., Kudoh, S., Saka, H., Nishimura, Y., Nakagawa, K., Fukuoka, M. S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706). *J Thorac Oncol*. 6(12):2069-75, 2011.
 14. Kudo, K., Ohyanagi, F., Horiike, A., Miyauchi, E., Yanagitani, N., Hoshi, R., Satoh, Y., Motoi, N., Hamanaka, W., Ishikawa, Y., Mun, M., Sakao, Y., Okumura, S., Nakagawa, K., Horai, T., Nishio, M. Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. *Lung Cancer*. 74:401-04, 2011.
 15. Makino, Y., Yamamoto, N., Sato, H., Ando, R., Goto, Y., Tanai, C., Asahina, H., Nokihara, H., Sekine, I., Kunitoh, H., Ohe, Y., Sugiyama, E., Yokote, N., Tamura, T., Yamamoto, H. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. *Cancer Chemother Pharmacol*, 2011 [Epub ahead of print].
 16. Asami, K., Koizumi, T., Hirai, K., Ameshima, S., Tsukadaira, A., Morozumi, N., Morikawa, A., Atagi, S., Kawahara, M. Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study. *Clin Lung Cancer*. 12:387-92, 2011.
 17. Maruyama, R., Hirai, F., Ondo, K., Kometani, T., Hamatake, M., Seto, T., Sugio, K., Ichinose, Y. Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: a single-center feasibility study. *Surg Today*. 41:1492-97, 2011.
 18. Nishio, M., Yamanaka, T., Matsumoto, K., Kimura, H., Sakai, K., Sakai, A., Sone, T., Horiike, A., Koizumi, F., Kasahara, K., Ohira, T., Ikeda, N., Saijo, N., Arai, T., Nishio, K. Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma. *J Thorac Oncol*. 6(11):1889-94, 2011.
 19. Kaira, K., Okumura, T., Nakagawa, K., Ohde, Y., Takahashi, T., Murakami, H., Naito, T., Endo, M., Kondo, H., Nakajima, T., Yamamoto, N. MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. *Pathol Oncol Res*, 2011 [Epub ahead of print].
 20. Kobayakawa, M., Inagaki, M., Fujimori, M., Hamazaki, K., Hamazaki, T., Akechi, T., Tsugane, S., Nishiwaki, Y., Goto, K., Hashimoto, K., Yamawaki, S., Uchitomi, Y. Serum brain-derived neurotrophic factor and antidepressant-naïve major depression after lung cancer diagnosis. *Jpn J Clin Oncol*. 41(10):1233-7, 2011.
 21. Shiroyama, T., Komuta, K., Imamura, F., Hirashima, T., Kijima, T., Tachibana, I., Kawase, I. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. *Lung Cancer*. 74(1):85-8, 2011.
 22. Tanizaki, J., Okamoto, I., Okamoto, K., Takezawa, K., Kuwata, K., Yamaguchi, H., Nakagawa, K. MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations. *Journal of Thoracic Oncology*. 6(10):1624-31, 2011.
 23. Hosomi, Y., Shibuya, M., Niho, S., Ichinose, Y., Kiura, K., Sakai, H., Takeda, K., Kudo, S., Eguchi, K., Matsui, K., Masuda, N., Ando, M., Watanabe, K. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. *Anticancer Res*. 31(10):3449-56, 2011.
 24. Nogami, N., Hotta, K., Kuyama, S., Kiura, K., Takigawa, N., Chikamori, K., Shibayama, T., Kishino, D., Hosokawa, S., Tamaoki, A., Harita, S., Tabata, M., Ueoka, H., Shinkai, T., Tanimoto, M. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or

- extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. *Lung Cancer*. 74(1):80-4, 2011.
25. Fujisaka, Y., Sugiyama, T., Saito, H., Nagase, S., Kudoh, S., Endo, M., Sakai, H., Ohashi, Y., Saijo, N. Randomised, phase III trial of epoetin-b to treat chemotherapy-induced anaemia according to the EU regulation. *British Journal of Cancer*. 105:1267-72, 2011.
 26. Saijo N. Preface for JCOG review series. *Jpn J Clin Oncol*. 41(10):1155, 2011.
 27. Horiike, A., Kudo, K., Miyauchi, E., Ohyanagi, F., Kasahara, K., Horai, T., Nishio, M. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. *Br J Cancer*. 105(8):1131-6, 2011.
 28. Kaira, K., Ohde, Y., Nakagawa, K., Okumura, T., Murakami, H., Takahashi, T., Kondo, H., Nakajima, T., Endo, M., Yamamoto, N. Thymidylate Synthase Expression is Closely Associated with Outcome in Patients with Pulmonary Adenocarcinoma. *Med Oncol*, 2011 [Epub ahead of print].
 29. Kaira, K., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Takahashi, T., Murakami, H., Shukuya, T., Kenmotsu, H., Naito, T., Hayashi, I., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., Yamamoto, N. 18F-FDG Uptake on PET in primary mediastinal non-thymic neoplasm: A clinico pathological study. *Eur J Radiol*, 2011 [Epub ahead of print].
 30. Hayashi, H., Okamoto, I., Morita, S., Taguri, M., Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. *Ann Oncol*, 2011 in press.
 31. Daga, H., Hida, T., Ishikawa, S., Shimizu, J., Tokunaga, S., Horio, Y., Kobayashi, K., Takeda, K. The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. *Jpn J Clin Oncol*. 41(9):1067-73, 2011.
 32. Nishino, K., Imamura, F., Kumagai, T., Uchida, J., Akazawa, Y., Okuyama, T., Tomita, Y. Small-cell lung carcinoma with long-term survival: A case report. *Oncol Lett*. 2:823-30, 2011.
 33. Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O., Cho, Y., Sun, J., Destro, A., Taira, K., Takeda, K., Okabe, T., Swanson, J., Itoh, H., Takada, M., Lifshits, E., Okuno, K., Engelman, JA., Shivdasani, RA., Nishio, K., Fukuoka, M., Varella-Garcia, M., Nakagawa, K., Jänne, PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci Transl Med*. 3(99):99ra86, 2011.
 34. Tanizaki, J., Okamoto, I., Sakai, K., Nakagawa, K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. *British Journal of Cancer*. 105(6):807-13, 2011.
 35. Osoegawa, A., Kometani, T., Nosaki, K., Ondo, K., Hamatake, M., Hirai, F., Seto, T., Sugio, K., Ichinose Y. LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. *Jpn J Clin Oncol*. 41:1132-37, 2011.
 36. Ohba, T., Sugio, K., Kometani, T., Yamaguchi, M., Hamatake, M., Nosaki, K., Takeoka, H., Kitajima, H., Hirai, F., Seto, T., Taguchi, K., Nishiyama, K., Shida, Y., Ichinose, Y. Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. *Lung Cancer*. 73:375-78, 2011.
 37. Tanaka, H., Kimura, T., Kudoh, S., Mitsuoka, S., Watanabe, T., Suzumura, T., Tachibana, K., Noguchi, M., Yano, S., Hirata, K. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. *Int J Cancer*. 129(6):1410-16, 2011.
 38. Imamura, F., Nishio, M., Noro, R., Tsuboi, M., Ikeda, N., Inoue, A., Ohsaki, Y., Kimura, Y., Nishino, K., Uchida, J., Horai, T. Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study). *Chemotherapy*. 57(4):357-62, 2011.
 39. Hirashima, T., Suzuki, H., Kobayashi, M., Kondoh, Y., Tokuoka, Y., Matsuura, Y., Tamiya, M., MorishiTa, N., Sasada, S., Okamoto, N., Akazawa, K., Kawase, I. Long-term chemotherapy may Prolong survival in advanced non-small-cell lung cancer among responders to first-line Chemotherapy. *Medical Oncology*, 2011 [Epub ahead of print].
 40. Naoki, K., Soejima, K., Okamoto, H., Hamamoto, J., Hida, N., Nakachi, I., Yasuda, H., Nakayama, S., Yoda, S., Satomi, R., Ikemura, S., Terai, H., Sato, T., Watanabe, K. The PCR-invader method (structure-specific 5' nuclease-based method), a

- sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. *Int J Clin Oncol.* 16:335-44, 2011.
41. Kobayashi, M., Matsui, K., Katakami, N., Takeda, K., Moriyama, A., Iwamoto, Y., Takada, M., Yoshioka, H., Sueoka, N., Nakagawa, K. for the West Japan Oncology Group. Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Pulmonary Adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. *Jpn J Clin Oncol.* 41(8):948-52, 2011.
 42. Kawakami, H., Sugioka, K., Yonesaka, K., Satoh, T., Shimomura, Y., Nakagawa, K. Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis. *J Clin Oncol.* 29(23):678-9, 2011.
 43. Lara, PN Jr., Douillard, JY., Nakagawa, K., Von Pawel, J., McKeage, MJ., Albert, I., Losonczy, G., Reck, M., Heo, DS., Fan, X., Fandi, A., Scagliotti, G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vandimezan (ASA404) in advanced non-small-cell lung cancer. *J Clin Oncol.* 29(22):2965-71, 2011.
 44. Asami, K., Kawahara, M., Atagi, S., Kawaguchi, T., Okishio, K. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. *Lung Cancer.* 73:211-6, 2011.
 45. Kozu, Y., Tsuta, K., Kohno, T., Sekine, I., Yoshida, A., Watanabe, S., Tamura, T., Yokota, J., Suzuki, K., Asamura, H., Furuta, K., Tsuda, H. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. *Lung Cancer.* 73:45-50, 2011
 46. Takahashi, T., Yamamoto, N., Tamura, T., Kunitoh, H., Nishiwaki, Y., Negoro, S. Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. *Oncol Lett.* 2:1033-40, 2011.
 47. Kenmotsu, H., Naito, T., Kimura, M., Ono, A., Shukuya, T., Nakamura, Y., Tsuya, A., Kaira, K., Murakami, H., Takahashi, T., Endo, M., Yamamoto, N. The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. *J Thorac Oncol.* 6(7):1242-6, 2011.
 48. Fukuoka, M., Wu, YL., Thongprasert, S., Sunpaweravong, P., Leong, SS., Sriuranpong, V., Chao, TY., Nakagawa, K., Chu, DT., Saijo, N., Duffield, EL., Rukazenzov, Y., Speake, G., Jiang, H., Armour, AA., To, KF., Yang, JC., Mok, TS. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). *J Clin Oncol.* 29(21):2866-74, 2011.
 49. Takeda, M., Okamoto, I., Hirabayashi, N., Kitano, M., Nakagawa, K. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. *Lung Cancer.* 73(1):103-09, 2011.
 50. Ogawa, S., Horio, Y., Yatabe, Y., Fukui, T., Ito, S., Hasegawa, Y., Mitsudomi, T., Hida, T. Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. *Int J Clin Oncol*, in press.
 51. Tada, T., Chiba, Y., Tsujino, K., Fukuda, H., Nishimura, Y., Kokubo, M., Negoro, S., Kudoh, S., Fukuoka, M., Nakagawa, K., Nakanishi, Y. A Phase I Study of Chemoradiotherapy with Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small-Cell Lung Cancer: WJTOG 3305. *Int J Radiat Oncol Biol Phys*, 2011 [Epub ahead of print].
 52. Tamiya, M., Sasada, S., Kobayashi, M., Uehara, N., Okamoto, N., Morishita, N., Suzuki, H., Hirashima, T., Kawahara, K., Kawase, I. Diagnostic Factors of Standard Bronchoscopy for Small(≤ 15 mm) Peripheral Pulmonary Lesions: A Multivariate Analysis. *InternMed.* 50:557-61, 2011.
 53. Okamoto, I., Yamamoto, N., Kubota, K., Ohe, Y., Nogami, N., Murakami, H., Yamaya, H., Ono, K., Nakagawa, K. Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. *Invest New Drugs*, 2011 [in press].
 54. Harada, H., Seto, T., Igawa, S., Tsuya, A., Wada, M., Kaira, K., Naito, T., Hayakawa, K., Nishimura, T., Masuda, N., Yamamoto, N. Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable locally-advanced non-small cell lung cancer (NSCLC); West Japan Thoracic Oncology Group WJTOG 3005-DI. *Int J Radiat Oncol Biol Phys*, 2011 [Epub ahead of print].

55. Kaira, K., Okumura, T., Ohde, Y., Takahashi, T., Murakami, H., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., Yamamoto, N. Correlation between 18F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors. *J Nucl Med.* 52(5):705-11, 2011.
56. Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., Endo, M., Takahashi, K., Yamamoto, N. The efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring EGFR mutations: A pooled analysis of published reports. *Cancer Sci.* 102(5):1032-7, 2011.
57. Ohyanagi, F., Horai, T., Sekine, I., Yamamoto, N., Nakagawa, K., Nishio, M., Senger, S., Morsli, N., Tamura, T. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. *Jpn J Clin Oncol.* 41(5):718-22, 2011.
58. Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., Yamamoto, N. A phase I study of oral panobinostat(LBH589) in Japanese patients with advanced solid tumors. *Invest New Drugs.* 2011 [Epub ahead of print].
59. Suyama, K., Naito, Y., Yoh, K., Niho, S., Goto, K., Ohmatsu, H., Nishiwaki, Y., Ohe, Y. Development of Cushing's syndrome during effective chemotherapy for small cell lung cancer. *Intern Med.* 50(4):335-8, 2011.
60. Niho, S., Kubota, K., Yoh, K., Goto, K., Ohmatsu, H., Nihei, K., Ohe, Y., Nishiwaki, Y. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis. *J Thorac Oncol.* 6(4):796-800, 2011.
61. Yamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., Tamura, T. Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 17:2528-37, 2011.
62. Hida, T., Tamiya, M., Nishio, M., Yamamoto, N., Hirashima, T., Horai, T., Tanii, H., Shi, MM., Kobayashi, K., Horio, Y. Phase I study of intravenous ASA404(vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. *Cancer Sci.* 102(4):845-51, 2011.
63. Takezawa, K., Okamoto, I., Nishio, K., Janne, P., Nakagawa, K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. *Clinical Cancer Research.* 17(8):2140-48, 2011.
- <平成 22 年度>
1. Kimura, T., Kudoh, S., Hirata, K. Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. *Clin Med Insights Oncol.* 5:23-34, 2011.
 2. Ichinose, Y., Seto, T., Nishiwaki, Y., Kiura, K., Sakai, H., Yokoyama, A., Segawa, Y., Ando, M., Watanabe, K. Phase I study of topotecan and cisplatin in patients with small cell lung cancer. *Jpn J ClinOncol.* 41(2):197-203, 2011.
 3. Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., Toyokuni, S., Osada, H., Sekido, Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. *Cancer Res.* 71:873-83, 2011.
 4. Sato, Y., Yamamoto, N., Kunitoh, H., Ohe, Y., Minami, H., Laird, NM., Katori, N., Saito, Y., Ohnami, S., Sakamoto, H., Sawada, JI., Saijo, N., Yoshida, T., Tamura, T. Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel. *J Thorac Oncol.* 6:132-38, 2011.
 5. Sekine, I., Kubota, K., Tamura, Y., Asahina, H., Yamada, K., Horinouchi, H., Nokihara, H., Yamamoto, N., Tamura, T. Innovator and generic cisplatin formulations: comparison of renal toxicity. *Cancer Sci.* 102:162-65, 2011.
 6. Yamaguchi, K., Shijubo, N., Kodama, T., Mori, K., Sugiura, T., Kuriyama, T., Kawahara, M., Shinkai, T., Iguchi, H., Sakurai, M. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. *Jpn J Clin Oncol.* 41:148-52, 2011.
 7. Takiguchi, Y., Seto, T., Ichinose, Y., Nogami, N., Shinkai, T., Okamoto, H., Minato, K., Seki, N., Eguchi, K., Kishi, K., Nishikawa, M., Watanabe, K. Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer: A Phase II Study. *J Thoracic Oncol.* 6(1):156-60, 2011.
 8. Kawaguchi, T., Ando, M., Kubo, A., Takada, M., Atagi, S., Okishio, K., Asami, K., Matsumura, A., Tsujino, K., Ignatius, OS., Sasaki, H. Long exposure of environmental tobacco smoke

- associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. *Clin Cancer Res.* 17: 39-45, 2011.
9. Takigawa, N., Kiura, K., Hotta, K., Hosokawa, S., Nogami, N., Aoe, K., Gemba, K., Fujiwara, K., Harita, S., Takemoto, M., Himej, K., Shinkai, T., Fujiwara, Y., Takata, S., Tabata, M., Kanazawa, S., Tanimoto, M. Okayama Lung Cancer Study Group. A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. *Lung Cancer.* 71(1):60-64, 2011.
 10. Okamoto, I., Takahashi, T., Okamoto, H., Nakagawa, K., Watanabe, K., Nakamatsu, K., Nishimura, Y., Fukuoka, M., Yamamoto, N. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. *Lung Cancer.* 72 (2) :199-204, 2011.
 11. Suzuki, H., Hirashima, T., Kobayashi, M., Sasada, S., Okamoto, N., Tamiya, M., Matsuura, Y., Morishita, N., Uehara, N., Matsui, K., Kawase, I. Prognosis of small-cell lung cancer since the introduction of amrubicin. *Med Oncol*28 (4) :1430-35, 2011.
 12. Takahashi, T., Nakamura, Y., Tsuya, A., Murakami, H., Endo, M., Yamamoto, N. Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. *Cancer Chemother Pharmacol.* 68(3):653-59, 2011.
 13. Tomita, N., Kodaira, T., Hida, T., Tachibana, H., Nakamura, T., Nakahara, R., Inokuchi, H. The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 76:1121-26, 2010.
 14. Masuda, N., Negoro, S., Hausheer, F., Nakagawa, K., Matsui, K., Kudoh, S., Takeda, K., Yamamoto, N., Yoshimura, N., Ohashi, Y., Fukuoka, M. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol.* 67(3):533-42, 2010.
 15. Takeda, K., Negoro, S., Tanaka, M., Fukuda, H., Nakagawa, K., Kawahara, M., Semba, H., Kudoh, S., Sawa, T., Saijo, N., Fukuoka, M. A Phase II Study of Cisplatin and Irinotecan As Induction Chemotherapy Followed by Concomitant Thoracic Radiotherapy with Weekly Low-dose Irinotecan in Unresectable, Stage III, Non-Small Cell Lung Cancer: JCOG 9706. *Jpn J Clin Oncol.* 41(1):25-31, 2010.
 16. Sakai, Y., Ohbayashi, C., Satouchi, M., Negoro, S., Yoshimura, M. Bronchial Brushing Cytology of Primary Signet-Ring Adenocarcinoma of the Lung. Another Morphological Feature on the Papanicolaou Smear : A Report of Two Cases. *Bronchial Brushing Cytology of sra.* 39(1):73-76, 2010.
 17. Naito, Y., Goto, K., Nagai, K., Ishii, G., Nishimura, M., Yoshida, J., Hishida, T., Nishiwaki, Y. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. *Chest.* 138(6):1411-17, 2010.
 18. Nagano, T., Yasunaga, M., Goto, K., Kenmotsu, H., Koga, Y., Kuroda, J., Nishimura, Y., Sugino, T., Nishiwaki, Y., Matsumura, Y. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. *Int J Cancer.* 127(11):2699-706, 2010.
 19. Maeda, J., Higashiyama, M., Imaizumi, A., Nakayama, T., Yamamoto, H., Daimon, T., Yamakado, M., Imamura, F., Kodama, K. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. *BMC Cancer.* 10:690, 2010.
 20. Okamoto, K., Okamoto, I., Okamoto, W., Tanaka, K., Takezawa, K., Kuwata, K., Yamaguchi, H., Nishio, K., Nakagawa, K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. *Cancer Res.* 70(24):10402-10, 2010.
 21. Okamoto, I., Yoshioka, H., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Asami, K., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Miyazaki, M., Tamura, K., Kurata, T., Fukuoka, M., Nakagawa, K. Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. *Journal of Clinical Oncology.* 28(36):5240-46, 2010.
 22. Lara, P., Chamsky, K., Shibata, T., Fukuoka, H., Tamura, T., Crowbey, J., Redmeme, MW., Natale, R., Saijo, N., Gandara, DR. Common arm comparative outcome analysis of phase III trials of cisplatin + irinotecan vs Cisplatin + Etoposide in extensive disease small cell lung cancer. *Cancer.* 116(24):5710-15, 2010.

23. Sato, S., Koike, T., Homma, K., Yokoyama, A. Ciliated muconodular papillary tumour of the lung: a newly defined low-grade malignant tumour. *Interact Cardiovasc Thorac Surg.* 11:685-87, 2010.
24. Okamoto, I., Takeda, K., Daga, H., Miyazaki, M., Yonesaka, K., Kiyota, H., Tsurutani, J., Ueda, S., Ichikawa, Y., Takeda, M., Sekiguchi, R., Tominaga, K., Enatsu, S., Nambu, Y., Nakagawa, K. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. *Lung Cancer.* 70(2):168-73, 2010.
25. Kenmotsu, H., Yasunaga, M., Goto, K., Nagano, T., Kuroda, J., Koga, Y., Takahashi, A., Nishiwaki, Y., Matsumura, Y. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. *Cancer.* 116(19):4597-604, 2010.
26. Okamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., Konishi, K., Arao, T., Nishio, K., Kaiser, R., Nakagawa, K. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. *Mol Cancer Ther.* 9(10):2825-33, 2010.
27. Kurata, T., Yamamoto, N., Komiya, T., Tsurutani, J., Miyazaki, M., Tamura, K., Takeda, K., Nakagawa, K., Fukuoka, M. A Phase I Study of Gemcitabine Plus Irinotecan for Advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). *Jpn J Clin Oncol.* 40(10):992-4, 2010.
28. Saijo, N. Multinational trial reveals striking regional differences. *ASCO POST.* 1:1-3, 2010.
29. Yoh, K., Kenmotsu, H., Yamaguchi, Y., Kubota, K., Ohmatsu, H., Goto, K., Niho, S., Ohe, Y., Saijo, N., Nishiwaki, Y. Severe interstitial lung disease associated with amrubicin treatment. *J Thorac Oncol.* 5(9):1435-38, 2010.
30. Nagano, T., Kim, YH., Goto, K., Kubota, K., Ohmatsu, H., Niho, S., Yoh, K., Naito, Y., Saijo, N., Nishiwaki, Y. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. *Lung Cancer.* 69(3):315-18, 2010.
31. Saijo, N. Progress in cancer chemotherapy with special stress on molecular-targeted therapy. *Jpn J Clin Oncol.* 40(9):855-62, 2010.
32. Saijo, N., Fukuoka, M., Thongprasert, S., Ichinose, Y., Mitsudomi, T., Mok, T., Ohe, Y., Park, K., Wu, Y-L. Lung cancer working group report. *Jpn J Clin Oncol.* 40 (Supplement I):i7-i12, 2010.
33. Saijo, N., Kenmotsu, H. Recent development of molecular targeted drug in lung cancer. *Int. Med.* 49:1923-34, 2010.
34. Seto, T., Yamanaka, T., Wasada, I., Seki, N., Okamoto, H., Ogura, T., Shibuya, M., Takiguchi, Y., Shinkai, T., Masuda, N., Ichinose, Y., Eguchi, K., Watanabe, K. Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. *Lung Cancer.* 69:213-17, 2010.
35. Kaira, K., Endo, M., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Takahashi, T., Murakami, H., Tsuya, A., Nakamura, Y., Naito, T., Hayashi, I., Serizawa, M., Koh, Y., Hanaoka, H., Tominaga, H., Oriuchi, N., Kondo, H., Nakajima, T., Yamamoto, N. Biological Correlation of 18F-FDG Uptake on PET in Thymic Epithelial Tumors. *J Clin Oncol.* 28(23):3746-53, 2010.
36. Yamamoto, N., Nakagawa, K., Nishimura, Y., Tsujino, K., Satouchi, M., Kudo, S., Hida, T., Kawahara, M., Takeda, K., Katakami, N., Sawa, T., Yokota, S., Seto, T., Imamura, F., Saka, H., Iwamoto, Y., Semba, H., Chiba, Y., Uejima, H., Fukuoka, M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. *J Clin Oncol.* 28(23):3739-45, 2010.
37. Ito, T., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Kubota, K., Nagai, K., Miyazaki, E., Kumamoto, T., Nishiwaki, Y. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. *J Thorac Oncol.* 5(7):976-80, 2010.
38. Yamamoto, N., Yamanaka, T., Ichinose, Y., Kubota, K., Sakai, H., Gemma, A., Saijo, N., Fukuoka, M., Niitani, H. Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. *Anticancer Res.* 30(7):2985-90, 2010.
39. Yamamoto, N., Nishiwaki, Y., Negoro, S., Jiang, H., Itoh, Y., Saijo, N., Fukuoka, M. Disease control as a predictor of survival with gefitinib and docetaxel in a Phase III study (V-15-32) in advanced non-small-cell lung cancer patients. *J Thorac Oncol.* 5(7):1042-47, 2010.
40. Horio, Y., Osada, H., Shimizu, J., Ogawa, S., Hida, T., Sekido, Y. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to

- cytotoxicity of amrubicin in human lung cancer cell lines. *Cancer Chemother Pharmacol.* 66:237-43, 2010.
41. Kobayashi, M., Matsui, K., Iwamoto, Y., Ebi, N., Oizumi, S., Takeda, K., Sawa, T., Shibata, K., Saka, H., Imamura, F., Seki, N., Saito, H., Goto, I., Nakagawa, K. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301. *J Thorac Oncol.* 5(7):1075-80, 2010.
 42. Masuda, N., Matsui, K., Negoro, S., Takeda, K., Kudoh, S., Nakagawa, K., Mukaiyama, A., Arase, H., Yoshida, P., Ijima, T., Takada, M., Fukuoka, M. Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. *Clin Lung Cancer.* 11(4):271-79, 2010.
 43. Segawa, Y., Kiura, K., Takigawa, N., Kamei, H., Harita, S., Hiraki, S., Watanabe, Y., Sugimoto, K., Shibayama, T., Yonei, T., Ueoka, H., Takemoto, M., Kanazawa, S., Takata, I., Nogami, N., Hotta, K., Hiraki, A., Tabata, M., Matsuo, K., Tanimoto, M. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. *J Clin Oncol.* 28(20):3299-306, 2010.
 44. Higashiyama, M., Oda, K., Okami, J., Maeda, J., Kodama, K., Imamura, F., Minamikawa, K., Takano, T., Kobayashi, H. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. *Lung Cancer.* 68(3):472-77, 2010.
 45. Takezawa, K., Okamoto, I., Tanizaki, J., Kuwata, K., Yamaguchi, H., Fukuoka, M., Nishio, K., Nakagawa, K. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. *Mol Cancer Ther.* 9(6):1647-56, 2010.
 46. Takeda, M., Okamoto, I., Fukuoka, M., Nakagawa, K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. *J Clin Oncol.* 28(17):e273-4, 2010.
 47. Ichinose, Y., Seto, T., Nishiwaki, Y., Ohe, Y., Yamada, Y., Takeda, K., Saijo, N., Hotta, T. Randomized phase 2 dose-finding study of weekly administration of darbeopetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. *Jpn J Clin Oncol.* 40:521-29, 2010.
 48. Kubota, K., Sakai, H., Yamamoto, N., Kunitoh, H., Nakagawa, K., Takeda, K., Ichinose, Y., Saijo, N., Ariyoshi, Y., Fukuoka, M. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. *J Thorac Oncol.* 5:702-06, 2010.
 49. Satouchi, M., Kotani, Y., Katakami, N., Shimada, T., Urata, Y., Yoshimura, S., Funada, Y., Hata, A., Ando, M., Negoro, S. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naive patients with advanced non-small cell lung cancer. *J Thorac Oncol.* 5(5):696-701, 2010.
 50. Tagawa, T., Osoegawa, A., Yamazaki, K., Okamoto, T., Kometani, T., Wataya, H., Seto, T., Fukuyama, S., Hirai, F., Sugio, K., Ichinose, Y. Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution. *J Surg Oncol.* 101:495-99, 2010.
 51. Yoshida, K., Yatabe, Y., Park, J., Ogawa, S., Park, JY., Shimizu, J., Horio, Y., Matsuo, K., Mitsudomi, T., Hida, T. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. *J Cancer Res Clin Oncol.* 136:527-35, 2010.
 52. Tajima, K., Ohashi, R., Sekido, Y., Hida, T., Nara, T., Hashimoto, M., Iwakami, S., Minakata, K., Yae, T., Takahashi, F., Saya, H., Takahashi, K. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. *Oncogene.* 29:1941-51, 2010.
 53. Park, JY., Matsuo, K., Suzuki, T., Ito, H., Hosono, S., Kawase, T., Watanabe, M., Oze, I., Hida, T., Yatabe, Y., Mitsudomi, T., Takezaki, T., Tajima, K., Tanaka, H. Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. *Carcinogenesis.* 31:660-65, 2010.
 54. Komuta, K., Osaki, T., Mori, M., Yokota, S., Tanio, Y., Matsui, K., Imamura, F., Kawase, I. A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable non-small cell lung cancer. *Chemotherapy.* 56(1):39-45, 2010.
 55. Yamazaki, K., Sugio, K., Yamanaka, T., Hirai, F., Osoegawa, A., Tagawa, T., Fukuyama, S., Wataya, H., Seto, T., Ichinose, Y. Prognostic factors in non-small cell lung cancer patients with

postoperative recurrence following third-generation chemotherapy. *Anticancer Res.* 30:1311-15, 2010.

<平成 21 年度>

1. Kohno, T., Kunitoh, H., Shimada, Y., Shiraishi, K., Ishii, Y., Goto, K., Ohe, Y., Nishiwaki, Y., Kuchiba, A., Yamamoto, S., Hirose, H., Oka, A., Yanagitani, N., Saito, R., Inoko, H., Yokota, J. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. *Carcinogenesis.* 31(5):834-41, 2010.
2. Kim, YH., Yoh, K., Niho, S., Goto, K., Ohmatsu, H., Kubota, K., Nishiwaki, Y. Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer. *Respir Med.* 104(3):434-49, 2010.
3. Ando, R., Makino, Y., Tamura, T., Yamamoto, N., Nishigaki, R., Kimura, T., Yokote, N., Yamamoto, H. Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: application to a clinical pharmacokinetic study. *Biomed Chromatogr.* 24:301-06, 2010.
4. Di Maio, M., Lama, N., Morabito, A., Smit, EF., Georgoulas, V., Takeda, K., Quoix, E., Hatzidaki, D., Wachters, FM., Gebbia, V., Tsai, CM., Camps, C., Schuette, W., Chiodini, P., Piccirillo, MC., Perrone, F., Gallo, C., Gridelli, C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. *Eur J Cancer.* 46:735-43, 2010.
5. Foster Martin, D., Saijo, N., Seymour, L. Calvert, H. Performing Phase I clinical trials of anticancer agents: Perspectives from within the European Union and Japan. *Clin Cancer Res.* 16(6):1737-44, 2010.
6. Takahashi, T., Yamamoto, N., Nukiwa, T., Mori, K., Tsuboi, M., Horai, T., Masuda, N., Eguchi, K., Mitsudomi, T., Yokota, S., Segawa, Y., Ichinose, Y., Fukuoka, M., Saijo, N. Phase II study of Erlotinib in Japanese patients with advanced non-small cell lung cancer. *Anticancer Research.* 30:557-64, 2010.
7. Takeda, K., Hida, T., Sato, T., Ando, M., Seto, T., Satouchi, M., Ichinose, Y., Katakami, N., Yamamoto, N., Kudoh, S., Sasaki, J., Matsui, K., Takayama, K., Kashii, T., Iwamoto, Y., Sawa, T., Okamoto, I., Kurata, T., Nakagawa, K., Fukuoka, M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). *J Clin Oncol.* 28(5):753-60, 2010.
8. Igawa, S., Murakami, H., Takahashi, T., Nakamura, Y., Tsuya, A., Naito, T., Kaira, K., Ono, A., Shukuya, T., Tamiya, A., Endo, M., Yamamoto, N. Efficacy of Chemotherapy with Carboplatin and Paclitaxel for Unresectable Thymic Carcinoma. *Lung Cancer.* 67(2):194-97, 2010.
9. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 11(2):121-28, 2010.
10. Yamane, Y., Ishii, G., Goto, K., Kojima, M., Nakao, M., Shimada, Y., Nishiwaki, Y., Nagai, K., Kohrogi, H., Ochiai, A. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. *J Thorac Oncol.* 5(1):49-55, 2010.
11. Kunitoh, H., Tamura, T., Shibata, T., Takeda, K., Katakami, N., Nakagawa, K., Yokoyama, A., Nishiwaki, Y., Noda, K., Watanabe, K., Saijo, N. JCOG Lung Cancer Study Group. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). *Br J Cancer.* 103:6-11, 2010.
12. Igawa, S., Watanabe, R., Ito, I., Murakami, H., Takahashi, T., Nakamura, Y., Tsuya, A., Kaira, K., Naito, T., Endo, M., Yamamoto, N., Kameya, T. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. *Lung Cancer.* 68:438-45, 2010.
13. Kaneda, H., Okamoto, I., Hayashi, H., Yoshioka, H., Miyazaki, M., Kudoh, S., Kimura, T., Sugiura, T., Sawa, T., Takeda, K., Iwamoto, S., Satouchi, M., Akita, K., Saito, H., Goto, I., Shibata, K., Fukuoka, M., Nakagawa, K. Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer Results of the West Japan Thoracic Oncology Group Trial (WJTOG401). *Journal of Thoracic Oncology.* 5(1):105-09, 2010.

14. Hotta, K., Kiura, K., Takigawa, N., Yoshioka, H., Hayashi, H., Fukuyama, H., Nishiyama, A., Yokoyama, T., Kuyama, S., Umemura, S., Kato, Y., Nogami, N., Segawa, Y., Yasugi, M., Tabata, M., Tanimoto, M. Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705. *J Thorac Oncol.* 5(10):1668-72, 2010.
15. Hida, T., Ogawa, S., Park, J.C., Park, J.Y., Shimizu, J., Horio, Y., Yoshida, K. Gefitinib for the treatment of non-small-cell lung cancer. *Expert Rev Anticancer Ther.* 9:17-35, 2009.
16. Fujii, T., Kunikane, H., Okamoto, H., Watanabe, K., Kunitoh, H., Mori, K., Yokoyama, A., Fukuda, H., Tamura, T., Saijo, N. A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510. *Jpn J Clin Oncol.* 39:784-90, 2009.
17. Okasaka, T., Matsuo, K., Suzuki, T., Ito, H., Hosono, S., Kawase, T., Watanabe, M., Yatabe, Y., Hida, T., Mitsudomi, T., Tanaka, H., Yokoi, K., Tajima, K. hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. *J Hum Genet.* 54:739-45, 2009.
18. Goto, Y., Shinjo, K., Kondo, Y., Shen, L., Toyota, M., Suzuki, H., Gao, W., An, B., Fujii, M., Murakami, H., Osada, H., Taniguchi, T., Usami, N., Kondo, M., Hasegawa, Y., Shimokata, K., Matsuo, K., Hida, T., Fujimoto, N., Kishimoto, T., Issa, J.P., Sekido, Y. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. *Cancer Res.* 69:9073-82, 2009.
19. Kano, Y., Tanaka, M., Akutsu, M., Mori, K., Yazawa, Y., Mano, H., Furukawa, Y. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. *Cancer Chemo Pharm.* 64:1129-37, 2009.
20. Kunitoh, H., Tamura, T., Shibata, T., Nakagawa, K., Takeda, K., Nishiwaki, Y., Osaki, Y., Noda, K., Yokoyama, A., Saijo, N.; JCOG Lung Cancer Study Group, Tokyo, Japan. A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). *Br J Cancer.* 101:1549-54, 2009.
21. Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., Mitsudomi, T. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with Lung adenocarcinoma who showed initial good response to gefitinib. *J Thorac Oncol.* 4:1415-19, 2009.
22. Maemondo, M., Masuda, N., Sekine, I., Kubota, K., Segawa, Y., Shibuya, M., Imamura, F., Katakami, N., Hida, T., Takeo, S. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. *Ann Oncol.* 20:1860-66, 2009.
23. Oze, I., Hotta, K., Kiura, K., Ochi, N., Takigawa, N., Fujiwara, Y., Tabata, M., Tanimoto, M. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer disappointing results. *PLoS One.* 4(11):e7835, 2009.
24. Kishida, Y., Kawahara, M., Teramukai, S., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., Nakano, K., Tsuboi, M., Shibata, K., Atagi, S., Kawaguchi, T., Furuse, K., Fukushima, M. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. *Br J Cancer.* 101: 1537-42, 2009.
25. Segawa, Y., Aogi, K., Inoue, K., Sano, M., Sekine, I., Tokuda, Y., Isobe, H., Ogura, T., Tsuboi, M., Atagi, S.; PALO Japanese Cooperative Study Group. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. *Ann Oncol.* 20:1874-80, 2009.
26. Wakelee, H., Loo, B.W. Jr., Kernstine, K.H., Putnam, J.B. Jr., Edelman, M.J., Vokes, E.E., Schiller, J.H., Baas, P., Saijo, N., Adjei, A., Goss, G., Choy, H., Gandara, D.R. Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review from the 10th Ann. Internat. Lung Cancer Congress. *Clin.Lung Cancer.* 10(6):398-404, 2009.
27. Maruyama, R., Wataya, H., Seto, T., Ichinose, Y. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. *Anticancer Res.* 29:4217-21, 2009.
28. Kim, Y.H., Kubota, K., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Saijo, N., Nishiwaki, Y. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. *Jpn J Clin Oncol.* 39(9):576-81, 2009.

29. Ishikawa, Y., Matsuguma, H., Nakahara, R., Suzuki, H., Ui, A., Kondo, T., Kamiyama, Y., Igarashi, S., Mori, K., Kodama, T., Yokoi, K. Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of etrapleural pneumonectomy. *Ann Thorac Surg.* 88:952-57, 2009.
30. Naoki, K., Kunikane, H., Fujii, T., Tsujimura, S., Hida, N., Okamoto, H., Watanabe, K. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. *Jpn J Clin Oncol.* 39:569-75, 2009.
31. Sangha, R., Lara, PN Jr., Adjei, AA., Baas, P., Choy, H., Gaspar, LE., Goss, G., Saijo, N., Schiller, JH., Vokes, EE., Gandara, DR. Cooperative Group Research Endeavors in Small Cell Lung Cancer: Current and Future Directions. *Clin Lung Cancer.* 110(5):322-30, 2009.
32. Sasada, S., Kawahara, K., Kusunoki, Y., Okamoto, N., Iwasaki, T., Suzuki, H., Kobayashi, M., Hirashima, T., Matsui, K., Ohta, M., Miyazawa, T. A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy. *Surg Endosc.* 23(8):1901-07, 2009.
33. Nagano, T., Yasunaga, M., Goto, K., Kenmotsu, H., Koga, Y., Kuroda, J., Nishimura, Y., Sugino, T., Nishiwaki, Y., Matsumura, Y. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. *Clin Cancer Res.* 15(13):4348-55, 2009.
34. Kim, YH., Ishii, G., Goto, K., Ota, S., Kubota, K., Murata, Y., Mishima, M., Saijo, N., Nishiwaki, Y., Ochiai, A. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. *Lung Cancer.* 65(1):105-11, 2009.
35. Goto, Y., Sekine, I., Sekiguchi, H., Yamada, K., Nokihara, H., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T. Differences in the quality of information on the internet about lung cancer between the United States and Japan. *J Thorac Oncol.* 4:829-33, 2009.
36. Kawaguchi, K., Murakami, H., Taniguchi, T., Fujii, M., Kawata, S., Fukui, T., Kondo, Y., Osada, H., Usami, N., Yokoi, K., Ueda, Y., Yatabe, Y., Ito, M., Horio, Y., Hida, T., Sekido, Y. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. *Carcinogenesis.* 30:1097-05., 2009.
37. Morita, S., Okamoto, I., Kobayashi, K., Yamazaki, K., Asahina, H., Inoue, A., Hagiwara, K., Sunaga, N., Yanagitani, N., Hida, T., Yoshida, K., Hirashima, T., Yasumoto, K., Sugio, K., Mitsudomi, T., Fukuoka, M., Nukiwa, T. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. *Clin Cancer Res.* 15:4493-98, 2009.
38. Mori, K., Kobayashi, H., Kamiyama, Y., Kano, Y., Kodama, T. A Phase II trial of Weekly Chemotherapy with Paclitaxel plus Gemcitabine as a First-Line Treatment in Advanced Non-Small Cell Lung Cancer. *Cancer Chemother Pharmacol.* 64:73-78, 2009.
39. Wataya, H., Okamoto, T., Maruyama, R., Seto, T., Yamazaki, K., Tagawa, T., Fukuyama, S., Osoegawa, A., Ikeda, J., Nishimura, M., Yamanaka, T., Ichinose, Y. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. *Lung Cancer.* 64:341-45, 2009.
40. Okuyama, T., Endo, C., Seto, T., Kato, M., Seki, N., Akechi, T., Furukawa, TA., Eguchi, K., Hosaka, T. Cancer patients' reluctance to discuss psychological distress with their physicians was not associated with underrecognition of depression by physicians: a preliminary study. *Palliat Support Care.* 7:229-33, 2009.
41. Takeda, K., Negoro, S., Tamura, T., Nishiwaki, Y., Kudoh, S., Yokota, S., Matsui, K., Semba, H., Nakagawa, K., Takada, Y., Ando, M., Shibata, T., Saijo, N. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). *Ann. Oncol.* 20(5):835-41, 2009.
42. Hotta, K., Kiura, K., Fujiwara, Y., Takigawa, N., Oze, I., Ochi, N., Tabata, M., Tanimoto, M. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. *Ann Oncol.* 20(5):829-34, 2009.
43. Matsubara, J., Ono, M., Negishi, A., Ueno, H., Okusaka, T., Furuse, J., Furuta, K., Sugiyama, E., Chiba, T., Saijo, N., Hirohashi, S. Yamada, T. Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine. *J Clin. Oncol.* 27(13):2261-68, 2009.
44. Saijo, N., Takeuchi, M., Kunitoh, H. Reasons for

response differences seen in the V15-32, INTEREST and IPASS trials. *Nature Rev. Clin. Oncol.* 6(6):287-94, 2009.

45. Ota, S., Ishii, G., Goto, K., Kubota, K., Kim, YH., Kojika, M., Murata, Y., Yamazaki, M., Nishiwaki, Y., Eguchi, K., Ochiai, A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. *Lung Cancer.* 64(1):98-104, 2009.
46. Tanai, C., Nokihara, H., Yamamoto, S., Kunitoh, H., Yamamoto, N., Sekine, I., Ohe, Y., Tamura, T. Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. *Br J Cancer.* 100:1037-42, 2009.
47. Suzuki, Y., Murakami, H., Kawaguchi, K., Taniguchi, T., Fujii, M., Shinjo, K., Kondo, Y., Osada, H., Shimokata, K., Horio, Y., Hasegawa, Y., Hida, T., Sekido, Y. Activation of PI3K-AKT pathway in human malignant mesothelioma cells. *Mol Med Report.* 2:181-88, 2009.

G. 知的所有権の取得状況

1. 特許取得
なし
2. 実用新案登録
なし
3. その他
なし

Ⅱ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

<平成 23 年度>

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Naito, T., Tanaka, F., Ono, F., Yoneda, K., Takahashi, T., Murakami, H., Nakamura, Y., Tsuya, A., Kenmotsu, H., Shukuya, T., Kaira, K., Koh, Y., Endo, M., Hasegawa, S., <u>Yamamoto, N.</u>	Prognostic impact of circulating tumor cells in patients with small-cell lung cancer	J Thorac Oncol	7(3)	512-19	2012
Tamiya, M., Suzuki, H., Kobayashi, M., Sasada, S., Okamoto, N., Morishita, N., Yasue, T., Matsuura, Y., <u>Hirashima, T.</u> , Kawase, I.	Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bonemetastasis from lung cancer	Med Oncol	29(1)	215-18	2012
Shimada, Y., Niho, S., Ishii, G., Hishida, T., Yoshida, J., Nishimura, M., Yoh, K., <u>Goto, K.</u> , Ohmatsu, H., Ohe, Y., Nagai, K.	Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens	Lung Cancer	75(3)	368-73	2012
Makino, Y., <u>Yamamoto, N.</u> , Sato, H., Ando, R., Goto, Y., Tanai, C., Asahina, H., Nokihara, H., Sekine, I., Kunitoh, H., Ohe, Y., Sugiyama, E., Yokote, N., <u>Tamura, T.</u> , Yamamoto, H.	Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer	Cancer Chemother Pharmacol			2011 [Epub ahead of print]